Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 2015

View Archived Issues

Bristol-Myers Squibb updates activities of fourth quarter 2014

Nanoliposomal irinotecan injection improves overall survival and objective response

Agios Pharmaceuticals discloses new inhibitors of mutant IDH2

Investigators in Japan patent novel P2X4 antagonists for pain

Biotie Therapies reports topline results from nepicastat study in cocaine dependence

New anti-IAPP MAbs disclosed by Neotope

Researchers prepare new synthetic vaccines for streptococcal infections

Roche reviews developments of fourth quarter 2014

Prezcobix approved in the U.S. for the treatment of adults with HIV-1

Astellas and Immunomic Therapeutics enter into agreement for JRC2-LAMP-vax

Valeant enters agreement to acquire Dendreon assets

Enrollment in phase IIb study of Ovasave for refractory Crohn's disease triggers payment to TxCell

Nuvo Research reports topline results of phase II WF-10 trial in allergic rhinitis

AstraZeneca, MD Anderson enter into collaboration for ovarian/gynecologic cancers

MicroConstants China in-licenses global rights to AA98 antibody-drug candidates

Sumitomo Dainippon Pharma reviews activities of third quarter of fiscal 2014

OPKO Health submits IND to begin phase IIa study of Factor VIIa-CTP

FDA approves Vyvanse for binge eating disorder

Xiapex approved in E.U. for Peyronie's disease

FDA approves first drug for Waldenstrom's macroglobulinemia

Pluristem releases further results from phase I/II trial of PLX-PAD in surgical muscle injury

Xencor reports results of study on XmAb-7195 in healthy volunteers

Breakthrough therapy designation granted Genentech's MPDL-3280A

Xencor releases topline phase Ib/IIa data for XmAb-5871

Management diagnostics receive two FDA orphan drug status

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...